Elanco Animal Health (ELAN) Stock Forecast & Price Target
$11.57B
Market Cap
-55.24
P/E
20.46
Forward P/E
46
Score
ELAN price $23.17 +0.52 +2.30%
Stocklytics score rationale: value 44, quality 42, growth 52.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 2913500000 | 2889000000 | 3066800000 | 3071000000 | 3273300000 | 4764000000 | 4411000000 | 4417000000 | 4439000000 | 4715000000 |
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and…
Consensus Buy from 18 analysts. Average price target $26.67, +15.1% versus the current price. Low $24.00. High $30.00.
Insights · Dividends · Forecast · Financials · Learn
Analysts have an average 12-month price target of $26.67 for Elanco Animal Health (ELAN), 15.1% above the current price of $23.17. Of 18 analysts covering the stock, 15 rate it Buy or Strong Buy, 3 Hold, and 0 Sell or Strong Sell, giving a consensus of Buy.
Forecasts are third-party estimates and often wrong. They are not investment advice.
| Low | $24.00 |
|---|---|
| Average | $26.67 |
| High | $30.00 |
The average is 15.1% above the current price of $23.17.
Of 18 analysts, 15 rate Elanco Animal Health Buy or Strong Buy, 3 Hold, and 0 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.
Analyst averages on file: 2026, EPS $1.13, revenue $5.14 billion. 2027, EPS $1.27, revenue $5.42 billion.
The Stocklytics Score for ELAN is 46 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.
$26.67 average, with a published range of $24.00 to $30.00.
The consensus is Buy from 18 analysts. This is not a recommendation.
Analysts' average EPS estimate for 2026 on file is $1.13. The average revenue estimate is $5.14 billion.
No reliable forecast exists that far out.
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Related: Elanco Animal Health · Financials · Dividends · Compare · AI stocks
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.
$11.57B
Market Cap
-55.24
P/E
20.46
Forward P/E
46
Score